<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><description>肿瘤学临床研究及制药企业研发评述</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 09 Jun 2021 21:33:35 +0800</pubDate><image><url>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</url><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>【你好，Doctor】刘澎教授分享第七届「多学科视野下骨髓瘤诊疗」高峰论坛会议亮点并浅谈MDT在骨髓瘤中的价值</title><link>https://mp.weixin.qq.com/s/S7qb9RwycBxIP2ehiVoqKw</link><description></description><content:encoded><![CDATA[【你好，Doctor】刘澎教授分享第七届「多学科视野下骨髓瘤诊疗」高峰论坛会议亮点并浅谈MDT在骨髓瘤中的价值]]></content:encoded><pubDate>Wed, 09 Jun 2021 21:10:23 +0800</pubDate></item><item><title>2021EHA好声音 | 维布妥昔单抗及PTCL/BCL领域核心研究会议日程</title><link>https://mp.weixin.qq.com/s/9PjWSvOm3tpPqcCpoy7dig</link><description></description><content:encoded><![CDATA[2021EHA好声音 | 维布妥昔单抗及PTCL/BCL领域核心研究会议日程]]></content:encoded><pubDate>Wed, 09 Jun 2021 21:10:23 +0800</pubDate></item><item><title>2021EHA好声音 | 鲍立教授：老年frail多发性骨髓瘤患者治疗方案的新探索——IAD与IRD方案</title><link>https://mp.weixin.qq.com/s/CsbBnfdDIeAJ3tMfvGDMZQ</link><description></description><content:encoded><![CDATA[2021EHA好声音 | 鲍立教授：老年frail多发性骨髓瘤患者治疗方案的新探索——IAD与IRD方案]]></content:encoded><pubDate>Wed, 09 Jun 2021 21:10:23 +0800</pubDate></item><item><title>【ASCO2021】CLN-081 1/2a期研究期中分析</title><link>https://mp.weixin.qq.com/s/f3Xnq-nGLIGbIEAQk6F8HA</link><description></description><content:encoded><![CDATA[【ASCO2021】CLN-081 1/2a期研究期中分析]]></content:encoded><pubDate>Wed, 09 Jun 2021 21:10:23 +0800</pubDate></item><item><title>读NEJM 涨知识 I Sotorasib治疗KRAS p.G12C突变肺癌</title><link>https://mp.weixin.qq.com/s/xKT3RAL3OfBYkqqPVDcRjA</link><description></description><content:encoded><![CDATA[读NEJM 涨知识 I Sotorasib治疗KRAS p.G12C突变肺癌]]></content:encoded><pubDate>Tue, 08 Jun 2021 21:48:03 +0800</pubDate></item><item><title>2021EHA 好声音 | 张薇教授解读含维布妥昔单抗的增强Beacopp方案治疗新诊断晚期霍奇金淋巴瘤患者</title><link>https://mp.weixin.qq.com/s/2O4RLIbxrTUuTF7mNR-9Gg</link><description></description><content:encoded><![CDATA[2021EHA 好声音 | 张薇教授解读含维布妥昔单抗的增强Beacopp方案治疗新诊断晚期霍奇金淋巴瘤患者]]></content:encoded><pubDate>Tue, 08 Jun 2021 21:48:03 +0800</pubDate></item><item><title>2021EHA好声音 | 复发难治多发性骨髓瘤（RRMM）药物治疗新进展</title><link>https://mp.weixin.qq.com/s/SOtRaBnNphxsUKl4NtoZ1A</link><description></description><content:encoded><![CDATA[2021EHA好声音 | 复发难治多发性骨髓瘤（RRMM）药物治疗新进展]]></content:encoded><pubDate>Tue, 08 Jun 2021 21:48:03 +0800</pubDate></item><item><title>2021EHA好声音 | 新诊断多发性骨髓瘤（NDMM）领域新进展</title><link>https://mp.weixin.qq.com/s/hXh8i7C53eX6GxKhhfCu6Q</link><description></description><content:encoded><![CDATA[2021EHA好声音 | 新诊断多发性骨髓瘤（NDMM）领域新进展]]></content:encoded><pubDate>Mon, 07 Jun 2021 21:13:35 +0800</pubDate></item><item><title>【ASCO2021】纳武利尤单抗VS培美曲塞联合卡铂治疗TKI耐药EGFR突变NSCLC二期研究结果</title><link>https://mp.weixin.qq.com/s/fUN-sUXFc8sprXPNzWPeEw</link><description></description><content:encoded><![CDATA[【ASCO2021】纳武利尤单抗VS培美曲塞联合卡铂治疗TKI耐药EGFR突变NSCLC二期研究结果]]></content:encoded><pubDate>Mon, 07 Jun 2021 21:13:35 +0800</pubDate></item><item><title>【ASCO2021】DZD9008治疗经治的EGFR 20外显子插入突变NSCLC一期研究初步结果</title><link>https://mp.weixin.qq.com/s/Ic6bZcbbePqEQ9bintSTLg</link><description></description><content:encoded><![CDATA[【ASCO2021】DZD9008治疗经治的EGFR 20外显子插入突变NSCLC一期研究初步结果]]></content:encoded><pubDate>Mon, 07 Jun 2021 21:13:35 +0800</pubDate></item><item><title>2021年6月5日安吉天荒坪放坡</title><link>https://mp.weixin.qq.com/s/D64CcUA6lUEt_ru1hXY2TA</link><description></description><content:encoded><![CDATA[2021年6月5日安吉天荒坪放坡]]></content:encoded><pubDate>Sun, 06 Jun 2021 00:01:04 +0800</pubDate></item><item><title>【EHA2021】OPTIC试验终点分析：3种PONATINIB的剂量优化研究</title><link>https://mp.weixin.qq.com/s/ljhPUJudrK2rmagoZBkyVg</link><description></description><content:encoded><![CDATA[【EHA2021】OPTIC试验终点分析：3种PONATINIB的剂量优化研究]]></content:encoded><pubDate>Sat, 05 Jun 2021 21:44:38 +0800</pubDate></item><item><title>【ASCO2021】Amivantamab联合Lazertinib治疗奥希替尼耐药NSCLC</title><link>https://mp.weixin.qq.com/s/KRG1eqDf5Faco6c-EHElWg</link><description></description><content:encoded><![CDATA[【ASCO2021】Amivantamab联合Lazertinib治疗奥希替尼耐药NSCLC]]></content:encoded><pubDate>Sat, 05 Jun 2021 21:44:38 +0800</pubDate></item><item><title>读NEJM 涨知识 I Olaparib辅助治疗BRCA1或BRCA2突变乳腺癌</title><link>https://mp.weixin.qq.com/s/FFhcrCRmkb_4aFahuIvUzQ</link><description></description><content:encoded><![CDATA[读NEJM 涨知识 I Olaparib辅助治疗BRCA1或BRCA2突变乳腺癌]]></content:encoded><pubDate>Fri, 04 Jun 2021 19:28:09 +0800</pubDate></item><item><title>【2847】【2021 ASCO】名家解读：金玉其质，冰雪之心—乳腺癌的希望之鸽PALOMA-3总生存结果更新</title><link>https://mp.weixin.qq.com/s/Nf5vd0bbjDh2l2DAqqCBfQ</link><description></description><content:encoded><![CDATA[【2847】【2021 ASCO】名家解读：金玉其质，冰雪之心—乳腺癌的希望之鸽PALOMA-3总生存结果更新]]></content:encoded><pubDate>Fri, 04 Jun 2021 19:28:09 +0800</pubDate></item><item><title>读NEJM 涨知识 I Nivolumab辅助治疗非肌层浸润尿路上皮癌</title><link>https://mp.weixin.qq.com/s/4gCeTmlq0uutcQGiIdJiCA</link><description></description><content:encoded><![CDATA[读NEJM 涨知识 I Nivolumab辅助治疗非肌层浸润尿路上皮癌]]></content:encoded><pubDate>Thu, 03 Jun 2021 21:34:25 +0800</pubDate></item><item><title>第四代EGFR抑制剂BLU-945开启1/2期临床研究</title><link>https://mp.weixin.qq.com/s/pZErtjFeKVYTuXPhogZEZA</link><description></description><content:encoded><![CDATA[第四代EGFR抑制剂BLU-945开启1/2期临床研究]]></content:encoded><pubDate>Thu, 03 Jun 2021 21:34:25 +0800</pubDate></item><item><title>40岁以下肺癌患者的基因组学</title><link>https://mp.weixin.qq.com/s/4HPZACnz4uCnJbNDLCkvCA</link><description></description><content:encoded><![CDATA[40岁以下肺癌患者的基因组学]]></content:encoded><pubDate>Thu, 03 Jun 2021 21:34:25 +0800</pubDate></item><item><title>ASCO I Brigatinib 日本一线治疗ALK阳性NSCLC患者结果</title><link>https://mp.weixin.qq.com/s/xL4HFmPF64zcMiUtKuISmA</link><description></description><content:encoded><![CDATA[ASCO I Brigatinib 日本一线治疗ALK阳性NSCLC患者结果]]></content:encoded><pubDate>Tue, 01 Jun 2021 23:03:29 +0800</pubDate></item><item><title>谷老师喊你戒烟啦</title><link>https://mp.weixin.qq.com/s/X30LDpc_nmyswIA_gD2wTw</link><description></description><content:encoded><![CDATA[谷老师喊你戒烟啦]]></content:encoded><pubDate>Tue, 01 Jun 2021 23:03:29 +0800</pubDate></item></channel></rss>